IRIS
LAURIA, FRANCESCO
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 8.075
EU - Europa 4.800
AS - Asia 3.097
SA - Sud America 630
AF - Africa 162
OC - Oceania 7
Continente sconosciuto - Info sul continente non disponibili 1
Totale 16.772
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 7.998
CN - Cina 1.208
GB - Regno Unito 1.016
RU - Federazione Russa 1.001
SG - Singapore 876
IE - Irlanda 775
UA - Ucraina 526
BR - Brasile 518
FR - Francia 381
SE - Svezia 373
VN - Vietnam 312
DE - Germania 267
HK - Hong Kong 263
IT - Italia 202
KR - Corea 158
FI - Finlandia 140
ZA - Sudafrica 90
IN - India 58
CA - Canada 40
AR - Argentina 38
BD - Bangladesh 35
IQ - Iraq 27
NG - Nigeria 21
TR - Turchia 21
ID - Indonesia 19
JP - Giappone 19
MX - Messico 19
EC - Ecuador 18
NL - Olanda 17
VE - Venezuela 17
BE - Belgio 16
ES - Italia 16
CZ - Repubblica Ceca 15
CO - Colombia 14
PK - Pakistan 14
UZ - Uzbekistan 13
PL - Polonia 12
AE - Emirati Arabi Uniti 9
DZ - Algeria 9
CL - Cile 8
EG - Egitto 8
AT - Austria 7
LT - Lituania 7
MY - Malesia 7
CI - Costa d'Avorio 6
JO - Giordania 6
KE - Kenya 6
MA - Marocco 6
PA - Panama 6
PY - Paraguay 6
SA - Arabia Saudita 6
AU - Australia 5
ET - Etiopia 5
HR - Croazia 5
NP - Nepal 5
PE - Perù 5
SN - Senegal 5
TH - Thailandia 5
EE - Estonia 4
IL - Israele 4
UY - Uruguay 4
AL - Albania 3
GR - Grecia 3
HN - Honduras 3
IR - Iran 3
KG - Kirghizistan 3
KH - Cambogia 3
AZ - Azerbaigian 2
BA - Bosnia-Erzegovina 2
BH - Bahrain 2
GE - Georgia 2
JM - Giamaica 2
LB - Libano 2
OM - Oman 2
PH - Filippine 2
PS - Palestinian Territory 2
QA - Qatar 2
SK - Slovacchia (Repubblica Slovacca) 2
TN - Tunisia 2
TT - Trinidad e Tobago 2
AM - Armenia 1
BG - Bulgaria 1
BO - Bolivia 1
BY - Bielorussia 1
CH - Svizzera 1
CR - Costa Rica 1
DK - Danimarca 1
DM - Dominica 1
DO - Repubblica Dominicana 1
EU - Europa 1
FJ - Figi 1
GA - Gabon 1
GM - Gambi 1
GT - Guatemala 1
GY - Guiana 1
HT - Haiti 1
KW - Kuwait 1
KZ - Kazakistan 1
LK - Sri Lanka 1
LU - Lussemburgo 1
Totale 16.761
Salva come PNG Salva come JPEG
Città #
Fairfield 1.164
Southend 896
Dallas 828
Dublin 772
Ashburn 622
Woodbridge 558
Singapore 470
Seattle 468
Jacksonville 433
Houston 421
Wilmington 417
Santa Clara 387
Cambridge 381
Chandler 369
Beijing 313
Moscow 296
Hong Kong 256
Ann Arbor 207
Hefei 179
Princeton 166
Seoul 156
Nanjing 155
San Jose 136
Ho Chi Minh City 114
The Dalles 100
Siena 89
Los Angeles 87
Lauterbourg 80
Johannesburg 79
Hanoi 62
São Paulo 55
Nanchang 52
San Diego 51
Boardman 49
Buffalo 45
Council Bluffs 45
Helsinki 44
San Mateo 36
New York 35
Shenyang 32
Tianjin 30
Orem 29
Munich 28
Shanghai 26
Hebei 25
Frankfurt am Main 24
London 23
San Francisco 23
Kunming 22
Abuja 20
Norwalk 20
Da Nang 19
Columbus 18
Redondo Beach 18
Tokyo 18
Toronto 18
Changsha 17
Dearborn 17
Hangzhou 17
Rio de Janeiro 17
Bengaluru 16
Brussels 16
Jiaxing 16
Dong Ket 14
Düsseldorf 13
Falls Church 13
Montreal 13
Ningbo 13
Zhengzhou 13
Baghdad 12
Brasília 12
Brno 12
Menlo Park 12
Nuremberg 12
Curitiba 11
Haiphong 11
Tashkent 11
Chennai 10
Chicago 10
Denver 10
Guayaquil 10
Washington 10
Belo Horizonte 9
Cape Town 9
Guarulhos 9
Porto Alegre 9
Turku 9
Izmir 8
Lancaster 8
Lanzhou 8
Warsaw 8
Brooklyn 7
Dhaka 7
Guangzhou 7
Hải Dương 7
Phoenix 7
Poplar 7
Stockholm 7
Taizhou 7
Abidjan 6
Totale 11.943
Salva come PNG Salva come JPEG
Nome #
A pilot monocentric analysis of efficacy and safety of Fludarabine-Campath combination (Flucam) as first line treatment in elderly patients with chronic lymphocytic leukaemia and Tp53 disfunction 288
A P210-derived multipeptide vaccine (CMLVAX100) induces reduction of “stable” minimal residual disease in chronic myeloid leukemia (CML) patients during treatment with Imatinib or alpha-Interferon 286
Activity of rituximab monotherapy in refractory splenic marginal zone lymphoma complicated with autoimmune hemolytic anemia 285
Long-term follow-up of 233 patients with hairy cell leukaemia, treated initially with pentostatin or cladribine, at a median of 16 years from diagnosis 270
Multicentre phase III trial on fludarabine, cytarabine (Ara-C), and idarubicin versus idarubicin, Ara-C and etoposide for induction treatment of younger, newly diagnosed acute myeloid leukaemia patients. 269
Selective influences in the expressed immunoglobulin heavy and light chain gene repertoire in hairy cell leukemia. 248
A case of i(11)(q10) as sole cytogenetic abnormality in a patient with acute lymphoblastic leukemia 248
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients 245
Insight into the behavior of hairy cell leukemia by immunogenetic analysis 240
BCR-ABL Derived Peptide Vaccine in Chronic Myeloid Leukemia Patients with Molecular Minimal Residual Disease During Imatinib: Interim Analysis of a Phase 2 Multicenter GIMEMA CML Working Party Trial 238
Alternative methods of cladribine administration 235
Impaired expression of p66Shc, a novel regulator of B-cell survival, in chronic lymphocytic leukemia 235
2-Chlorodeoxyadenosine in the treatment of relapsed/refractory chronic lymphoproliferative disorders 234
Complete molecular response in CML after p210 BCR-ABL1-derived peptide vaccination 230
Consensus guidelines for the diagnosis and management of patients with classic hairy cell leukemia 229
Lack of allelic exclusion by secondary rearrangements of tumour B-cell receptor light chains in hairy cell leukaemia 226
Incidence of bacterial and fungal infections in newly diagnosed acute myeloid leukaemia patients younger than 65 yr treated with induction regimens including fludarabine: retrospective analysis of 224 cases 225
A case of acute myelogenous leukemia: myelodysplastic syndrome with t(2;11)(p21;q23) without MLL rearrangement 224
Chromosome 14q32 translocations involving the immunoglobulin heavy chain locus in chronic lymphocytic leukaemia identify a disease subset with poor prognosis 221
Molecular cytogenetic analysis of B-CLL patients with aggressive disease 214
Emerging drugs in chronic myelogenous leukaemia 212
Absence of surface CD27 distinguishes hairy cell leukemia from other leukemic B-cell malignancies 211
Multicentre validation of a prognostic index for overall survival in chronic lymphocytic leukaemia 211
Alpha-interferon as maintenance drug after initial fludarabine therapy for patients with chronic lymphocytic leukemia and low-grade non-Hodgkin's lymphoma 211
The host genetic background of DNA repair mechanisms is an independent predictor of survival in diffuse large B-cell lymphoma 210
A t(20;21)(q12;q22.3) in a patient with chronic myelocytic leukemia in blastic phase [3] 210
Towards the pharmacotherapy of hairy cell leukaemia 205
Genome-wide DNA analysis identifies recurrent imbalances predicting outcome in chronic lymphocytic leukaemia with 17p deletion 202
Molecular insight into the biology and clinical course of hairy cell leukemia utilizing immunoglobulin gene analysis 201
CD30 positive (non-anaplastic) peripheral T-cell lymphoma of the thyroid gland 200
Pilot study of gemtuzumab ozogamicin (GO), fludarabine, cytarabine and idarubicin combined regimen (GO-FLAI) as first-line induction therapy plus GO alone as consolidation therapy for elderly acute myeloid leukemia patients. 199
Effect of a p210 multipeptide vaccine associated with imatinib or interferon in patients with chronic myeloid leukaemia and persistent residual disease: a multicentre observational trial. 199
Thrombotic thrombocytopenic purpura secondary to an occult adenocarcinoma 198
Azacitidine Low-Dose Schedule In Low-Risk Myelodysplastic Syndromes. Preliminary Results of a Multicenter Phase II Study 197
IGHV gene mutational status and 17p deletion are independent molecular predictors in a comprehensive clinical-biological prognostic model for overall survival prediction in chronic lymphocytic leukemia 196
The prognostic value of TP53 mutations in chronic lymphocytic leukemia is independent of Del17p13: implications for overall survival and chemorefractoriness 196
Molecular and clinical features of chronic lymphocytic leukaemia with stereotyped B cell receptors: results from an Italian multicentre study 195
Rituximab with pentostatin or cladribine: an effective combination treatment for hairy cell leukemia after disease recurrence 193
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with chronic lymphoproliferative disorders. 193
Hairy cell leukemias with unmutated IGHV genes define the minor subset refractory to single-agent cladribine and with more aggressive behavior. 193
Predicting the clinical course of Hodgkin lymphoma 189
The effects of zoledronic acid on serum lipids in multiple myeloma patients 187
CD34+/Ph+ cells are still detectable in chronic myeloid leukemia patients with sustained and prolonged complete cytogenetic remission during treatment with imatinib mesylate 186
Bcr-abl peptides for chronic myeloid leukemia. 186
Complete molecular remission induced by concomitant cladribine--rituximab treatment in a case of multi-resistant hairy cell leukemia 185
Trisomy 12 and t(14;22)(q32;q11) in a patient with B-cell chronic lymphocytic leukemia 183
Lenalidomide on alternative days is effective in myelodysplastic syndrome with 5q- deletion 182
Revisiting the definition of somatic mutational status in B-cell tumors: does 98% homology mean that a V(H)-gene is unmutated? 181
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia 179
Typical genomic imbalances in primary MALT lymphoma of the orbit 177
Reply to “Rituximab activity in CD20-positive multiple myeloma” 176
Low-dose oral fludarabine plus cyclophosphamide in elderly patients with untreated and relapsed or refractory chronic lymphocytic Leukaemia 174
The role of rituximab in combination with pentostatin or cladribine for the treatment of recurrent/refractory hairy cell leukemia 171
V-H and V-L genes in hairy cell leukemia reveal a dynamic on-going modification of the surface B-cell receptor 169
Cost of illness in patients with multiple myeloma in Italy: The CoMiM study 166
Comparison of low-dose versus standard-dose alpha-interferon regimen in the hairy cell leukemia treatment 164
Translocation(X;2)(q26;q11.2) in a patient with acute myeloid leukemia M2 evolved from essential thrombocytemia 163
CD56 and PGP expression in acute myeloid leukemia: impact on clinical outcome 163
Tumor cells of hairy cell leukemia express multiple clonally related immunoglobulin isotypes via RNA splicing 162
Very late relapse in a patient with chronic myeloid leukemia in sustained complete cytogenetic response under imatinib 162
Favorable impact of low-dose fludarabine plus epirubicin and cyclophosphamide regimen (FLEC) as treatment for low-grade non-Hodgkin's lymphomas 160
Incidence of novel N-glycosylation sites in the B-cell receptor of lymphomas associated with immunodeficiency 158
Combination therapies to improve the long-term outcome in hairy cell leukemia 157
Hairy cell leukemia: at the crossroad of somatic mutation and isotype switch 157
Reduction of imatinib dose and persistence of complete molecular response after p210 multipeptide vaccine in chronic myeloid leukaemia treated with dose escalation for acquired resistance 155
Vaccinoterapia antitumorale: il modello della leucemia mieloide cronica. 153
Case-control study of multidrug resistance phenotype and response to induction treatment includine or not fludarabine in newly diagnosed acute myeloid leukemia patients 151
Safety and efficacy of bortezomib, melphalan and low doses dexamethasone (VM-dex) in newly diagnosed patients with multiple myeloma 150
Efficacy of anti-CD20 monoclonal antibodies (Mabthera) in patients with progressed hairy cell leukemia 148
Idiopathic Hypereosinophilic Syndrome (HES) with FIP1L1-PDGFRA Rearrangement Can Be Effectively Treated with Imatinib 147
Hairy cell leukemias (HCL) with unmutated V-genes have a poorer response to single agent 2CdA than HCL with mutated V-genes 146
Efficacy and toxicity of FLAI vs ICE for induction treatment of newly diagnosed AML patients, younger than 60 years 142
Extramedullary intracranial localization of multiple myeloma and treatment with novel agents: A retrospective survey of 50 patients 142
High bcl-2 expression in acute myeloid leukemia cells correlates with CD34 positivity and complete remission rate 141
CMLVAX100 Peptide Vaccinations induce Peptide Specific "cytotoxic" CD4+ T Cells (CD4+CTLs) in Chronic Myeloid Leukemia Patients: New Insights about Peptide Vaccine-Mediated Antitumor Response 140
Hyperlipidemic myeloma 136
Complete resolution of hepatic aspergillosis after non-myeloablative hematopoietic stem cell transplantation in a patient with acute myeloid leukemia 135
Deletion 9q in a patient with concomitant myelodisplasia and non-Hodgkin lymphoma 131
EFFICACY OF ANTI-CD20 MONOCLONAL ANTIBODIES (MABTHERA) IN PATIENTS WITH PROGRESSED HAIRY CELL LEUKEMIA. 131
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype 129
Low-grade non Hodgkin's lymphomas in the elderly: impact of a low-dose fludarabine-based combination regimen (mini-FLEC) 128
Evaluation of Ph+/CD34+ residual cells in chronic myeloid leukemia patients after long lasting treatment with imatinib mesylate 127
Massive intravascular hemolysis: a fatal complication of Clostridium perfringens septicemia in a patient with acute lymphoblastic leukemia 126
Imatinib mesylate in the treatment of c-kit positive acute myeloid leukemia: is the real target? 121
Weekly administration of 2-chlorodeoxyadenosine in patients with hairy-cell leukemia : a new treatment schedule effective and safer in preventing infective complications 121
Long-term follow-up of non-Hodgkin's lymphoma patients treated with ProMACE-CytaBOM: an effective regimen for the intermediate grade subtype 116
Disseminated mucormycosis in a patient with acute myeloblastic leukemia misdiagnosed as infection by Entercoccus faecium 114
Long-lasting complete remission in patients with hairy cell leukemia trated with 2-CdA: a 5-year survey 110
Imatinib plus CMLVAX100 (P210-derived multipeptide vaccine): induction of complete molecular responses in patients with chronic myeloid leukemia (CML) showing persistent residual disease during treatment with imatinib mesylate 108
Low-dose fludarabine and cyclophosohamide in elderly patients with B-cell chronic lymphocytic leukemia refractory in conventional theraphy 108
Promyelocytic blast crisis of chronic myelogenous leukaemia during imatinib treatment. 107
Imatinib mesylate in the treatment of newly diagnosed or refractory/resistant c-KIT positive acute myeloid leukemia. Results of an Italian Multicentric Phase II Study 80
Hairy cell leukemia and COVID-19 adaptation of treatment guidelines 78
null 34
297. Gozzetti A.,Tozzuoli D., Crupi R., Gentili S., Raspadori D., Fabbri A., Lauria F. A t(20;21) (q2;q22.3) in a patient with chronic myelocytic leukemia in blastic phase. 4
Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients. 4
Combination therapies to improve the long-term outcome in hairy cell leukemia. 2
High density genome-wide DNA profiling reveals a remarkably stable profile in hairy cell leukaemia. 2
Totale 16.826
Salva come PNG Salva come JPEG
Categoria #
all - tutte 50.306
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 50.306
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021320 0 0 0 0 0 0 0 0 0 90 134 96
2021/20221.021 66 145 43 75 39 33 47 39 57 127 104 246
2022/20231.427 107 120 227 194 139 296 24 99 130 18 53 20
2023/2024977 40 17 78 61 21 280 371 4 5 12 5 83
2024/20252.145 56 111 193 103 318 118 34 111 180 90 203 628
2025/20264.552 433 800 630 609 842 197 462 158 202 219 0 0
Totale 16.826